Skip to main content

Table 2 Baseline characteristics of patients in the post hoc subgroup analysis

From: A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI

Parameter

Better efficacy subgroup

ITT population

FOLFIRI-Placebo

FOLFIRI-Aflibercept

FOLFIRI-Placebo

FOLFIRI-Aflibercept

(n = 406)

( n = 404)

( n = 614)

( n = 612)

Gender, n (%)

    

Female

174 (42.9)

153 (37.9)

261 (42.5)

247 (40.4)

Male

232 (57.1)

251 (62.1)

353 (57.5)

365 (59.6)

Mean age, y (range)

59.9 (25–86)

59.4 (21–82)

60.2 (19–86)

59.5 (21–82)

Age group, n (%)

    

<65 y

254 (62.6)

277 (68.6)

376 (61.2)

407 (66.5)

≥65 but <75 y

133 (32.8)

108 (26.7)

199 (32.4)

172 (28.1)

≥75 y

19 (4.7)

19 (4.7)

39 (6.4)

33 (5.4)

Race, n (%)

    

Asian

29 (7.1)

23 (5.7)

51 (8.3)

35 (5.7)

Black

14 (3.4)

11 (2.7)

27 (4.4)

16 (2.6)

White

355 (87.4)

361 (89.4)

523 (85.2)

548 (89.5)

Other

8 (2)

9 (2.2)

13 (2.1)

13 (2.1)

Cancer diagnosis category, n (%)

 

Colon

187 (46.1)

188 (46.5)

302 (49.2)

289 (47.2)

Rectosigmoid

95 (23.4)

85 (21)

136 (22.1)

123 (20.1)

Rectum

123 (30.3)

129 (31.9)

174 (28.3)

197 (32.2)

Other

1 (0.2)

2 (0.5)

2 (0.3)

3 (0.5)

Number of organs with metastasis, n (%)

    

  0

2 (0.5)

2 (0.5)

6 (1.0)

2 (0.3)

  1

237 (58.4)

230 (56.9)

271 (44.1)

256 (41.8)

  >1

167 (41.1)

172 (42.6)

337 (54.9)

354 (57.8)

Metastatic sites, n (%)

    

  Liver

283 (69.7)

294 (72.8)

431 (70.2)

459 (75.0)

  Lung

160 (39.4)

152 (37.6)

277 (45.1)

271 (44.3)

  Lymph

88 (21.7)

100 (24.8)

181 (29.5)

173 (28.3)

Liver metastasis only, n (%)

134 (33)

141 (34.9)

146 (23.8)

153 (25.0)

ECOG performance status, n (%)

    

  0

314 (77.3)

317 (78.5)

350 (57.0)

349 (57.0)

  1

92 (22.7)

87 (21.5)

250 (40.7)

250 (40.8)

  2

0

0

14 (2.3)

13 (2.1)

Prior bevacizumab, n (%)

    

  Yes

133 (32.8)

132 (32.7)

187 (30.5)

186 (30.4)

  No

273 (67.2)

272 (67.3)

427 (69.5)

426 (69.6)

  1. ECOG, European Cooperative Oncology Group; FOLFIRI, 5-fluorouracil–leucovorin–irinotecan; ITT, intent to treat; PS, performance status.